Migraine affects approximately 44 million people in the United States and one billion people globally. The personal, professional, and financial costs through lost productivity and quality of life are immense. Despite its prevalence and impact on individuals, families, and society, migraine is under-recognized, underdiagnosed, and undertreated.
Interviews with patients integrated into the educational activities uncovered chronic migraine episodes that sidelined careers,
New agents targeting the calcitonin gene-related peptide (CGRP) pathway have shown great promise and have led to excitement within the migraine community. Our goal for the Migraine Digital Hub is to provide educational activities, clinical information, resources, and assessment for the diagnosis and management of migraine. Our end goal is to improve the lives of individuals with migraine.
Charles A. The Pathophysiology of Migraine: Implications for Clinical Management. Lancet Neurol. 2018;17(2):174-182. (LINK)
Skljarevski V, et al. Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention: A Randomized Clinical Trial. JAMA Neurol. 2018;75(2):187-193. (LINK)
Goadsby P, et al. A Controlled Trial of Erenumab for Episodic Migraine. N Engl J Med. 2017;377:2123-2132. (LINK)
Silberstein SD, et al. Fremanezumab for the Preventive Treatment of Chronic Migraine. N Engl J Med. 2017:377(22):2113-2122. (LINK)
Charles A. Migraine. N Engl J Med. 2017;377(6):553-561. (LINK)
Buse DC, et al. Impact of Migraine on the Family: Perspectives of People with Migraine and Their Spouse/Domestic Partner in the CaMEO Study. Mayo Clin Proc. 2016 Apr 25. [Epub ahead of print] (LINK)